Navigation Links
Morria Biopharmaceuticals Plc Announces Positive Clinical Results for MRX-4 in its Phase II Clinical Study in Allergic Rhinitis Patients
Date:11/6/2008

cant milestone for Morria in advancing its anti-inflammatory program," stated Mark Cohen, Morria chairman. "We look forward to partnering our allergic rhinitis program as well as our dermatology and inflammatory bowel disease (IBD) programs with potential companies interested in these markets as well as our platform based lipid technology."

ABOUT ALLERGIC RHINITIS

Allergic rhinitis is a common condition that affects 20%-25% of people in the industrialized world with a market of close to $10 billion. Allergic rhinitis is characterized by inflammation of the nasal membranes accompanied by symptoms that may include sneezing, nasal congestion, nasal itching and rhinorrhea.

ABOUT MORRIA BIOPHARMACEUTICALS Plc

Morria Biopharmaceuticals Plc is a biopharmaceutical company focused on the development of novel, anti-inflammatory pharmaceuticals termed multi-functional anti-inflammatory drugs (MFAIDs). This class of drugs uniquely combines two promising approaches to preventing and reversing inflammation: first, they control the phospholipase A2 (PLA2) enzyme family, a known anti-inflammatory drug target. At the same time, they also enrich the cell surface glycosaminoglycans thereby protecting the cell against inflammatory agents. Morria is determined to become a pivotal player in the anti-inflammatory drug market by developing and commercializing novel drugs for respiratory, dermatology, pulmonary, gastro-intestinal and allergic inflammatory diseases. For more information, please visit http://www.morria.com.

This is not an invitation nor is it an offer to purchase or subscribe for shares. This release is only intended for persons falling within the exception set out in regulation 47 of the Financial Promotion order - Persons in the business of disseminating information.

Richard Lewis Communications, Inc.

212-827-0020

Cecelia Heer, Investors


SOURCE Morria Biopharmaceuticals Plc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Morria Biopharmaceuticals Plc to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
2. Morria Biopharmaceuticals Plc Announces Results From its Pre-Clinical Screening of Novel Anti-Inflammatory Compounds
3. Morria Biopharmaceuticals Plc Appoints Dr. Johnson Lau and Dr. David Sidransky to Board of Directors
4. Morria Biopharmaceuticals Plc Announces Appointment of Dr. Rosemary Mazanet as Interim Chief Executive Officer
5. Keryx Biopharmaceuticals Notified that Nasdaq Has Extended Minimum Bid Price Rule Compliance Period
6. Nomad Bioscience: New Plant Biotechnology Company Founded to Focus on Biomaterials and Biopharmaceuticals
7. Bayer Broadens Its Manufacturing Basis for Biopharmaceuticals in Tobacco Plants
8. XTL Biopharmaceuticals Receives Notice of Non-Compliance with Nasdaq Marketplace Rule Due to Changes in Board Composition
9. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
10. Keryx Biopharmaceuticals to Present at the Jefferies & Co. Healthcare Conference
11. XTL Biopharmaceuticals Announces Appointment of Laurence N. Charney to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... Rockville, MD (PRWEB) September 17, 2014 ... Small Business Innovation Research (SBIR) grant to support the ... award will provide ITI with approximately $255,000 over one ... a leading cause of food allergy, affect over one ... anaphylaxis behind peanut allergy. Tree nut exposure is also ...
(Date:9/17/2014)... , Sept. 17, 2014 Intarcia Therapeutics, ... data from a study of the cost and predictability ... 50 th Annual Meeting of the European Association ... session today, Christian Frois , Ph.D., of Analysis ... series of planned Intarcia-sponsored, retrospective studies to characterize the ...
(Date:9/17/2014)... LAUDERDALE, Fla. , Sept. 17, 2014 Alternative ... an agreement to form a Special Purpose Vehicle in partnership ... based Jatropha centric agro energy company. The SPV shall be ... registered entity with AFAI as majority shareholder. The SPV shall ... Africa , particularly Ethiopia . ...
(Date:9/17/2014)... FRANCISCO, Calif. , Sept. 17, 2014 ... a molecular diagnostics company pioneering the field of molecular ... to chief operating officer. Mr. Hall joined ... the company,s commercial entry into endocrinology. Since 2012, he ... as well as managed care and billing functions. As ...
Breaking Biology Technology:Immunomic Therapeutics Awarded SBIR Grant to Develop Multi-Nut Allergy Immunotherapy 2Immunomic Therapeutics Awarded SBIR Grant to Develop Multi-Nut Allergy Immunotherapy 3Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 2Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 3Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 4Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 5AFAI Signs Joint Venture Agreement With Jatro Greentech Inc. 2AFAI Signs Joint Venture Agreement With Jatro Greentech Inc. 3Veracyte, Inc. Announces Promotion of Christopher M. Hall To Chief Operating Officer 2Veracyte, Inc. Announces Promotion of Christopher M. Hall To Chief Operating Officer 3Veracyte, Inc. Announces Promotion of Christopher M. Hall To Chief Operating Officer 4
... This release is available in German . ... magic word in electronics. Dr. Willi Auwaerter and Professor Johannes ... Universitaet Muenchen (TUM), have now presented a novel molecular switch ... functionality of the switch is the position of a single ...
... Therapeutics, Inc. today announced that Ivan Bergstein, MD, the ... the Oppenheimer 22nd Annual Healthcare Conference on Wednesday, December ... Astoria Hotel in New York City. ... Inc. is a clinical stage biopharmaceutical company developing novel ...
... 2011 Syndax Pharmaceuticals, Inc. announced today ... study, demonstrated entinostat, a novel, oral small molecule inhibitor ... single agent in patients with relapsed or refractory Hodgkin,s ... 11, from 6:00 to 8:00 PM PT at the ...
Cached Biology Technology:The smallest conceivable switch 2Stemline Therapeutics, Inc. to Present at the Oppenheimer 22nd Annual Healthcare Conference 2Entinostat Demonstrates Activity in Hodgkin's Lymphoma 2Entinostat Demonstrates Activity in Hodgkin's Lymphoma 3Entinostat Demonstrates Activity in Hodgkin's Lymphoma 4Entinostat Demonstrates Activity in Hodgkin's Lymphoma 5
(Date:9/17/2014)... University] After decades of decline, grasses have returned ... the eye, the marsh in those places seems healthy ... key service of the marsh coastal protection ... the ecosystem function hasn,t come back," said ecologist Mark ... of the study in the journal Biological Conservation ...
(Date:9/16/2014)... Center for Children,s Environmental Health at the Mailman School ... association between childhood asthma and prenatal exposure to two ... Results appear online in the journal Environmental Health ... during pregnancy to higher levels of the chemicals, butylbenzyl ... percent and 78 percent increase in risk of developing ...
(Date:9/16/2014)... on September 13, 2014. The fire is human-caused and ... 2,300 acres in size and is mostly being fueled ... calm Monday night due to higher humidity. Yesterday ... beginning to construct a fireline on the West and North ... on the fire: , 7 20-person Crews, 4 Hot Shot ...
Breaking Biology News(10 mins):Cape Cod saltmarsh recovery looks good, falls short 2Cape Cod saltmarsh recovery looks good, falls short 3Phthalates heighten risk for childhood asthma 2Phthalates heighten risk for childhood asthma 3
... launched a key initiative to keep Europe at the forefront ... cell therapies to restore lost, damaged, or ageing cells and ... body,s ,master cells, that have not yet been programmed to ... of stem cells, and it is becoming clear that if ...
... (TWIC) Program, Ensures No Fraudulent Duplicate Enrollments ... Fla., June 17 ID Solutions, Inc., ... trusted,credential assurance, reported that it has been ... the Transportation Security Agency,s (TSA,s),TWIC program. The ...
... its latest state of the environment report, released ... environmental issues facing the NAFTA partners. The ... biodiversity and ecosystems, and pollution. Specific topics include ... vaquita porpoiseand the quality and quantity of water ...
Cached Biology News:European Science Foundation aims to strengthen 'regenerative medicine' 2ID Solutions Awarded Full-Production Order for Fingerprint Processing Software for TWIC 2New report looks at the state of the North American environment 2
... precision pressure regulator and pressurized syringe holder for ... Steady flow rate Microinjecting Fine ... Can be added to any new or existing ... manufacturer, even homemade. Connect to house air or ...
Chicken polyclonal to UCK2 ( Abpromise for all tested applications). Antigen: Full length protein, corresponding to amino acids 1-261 of Human UCK2 Entrez Gene ID: 7371 Swiss Protein ID: ...
Physical Form: powder Color: white Removes FLAG peptide from N-terminal and Met-N-terminal fusion proteins. Supplied with optimized enterokinase buffer....
Features , Designed to assist users in applying domed caps to tube strips and plates , Minimises the pressure required to seal the caps effectively , Enables multiple tubes to be sealed simultaneousl...
Biology Products: